Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy L Comstock

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Clinical Ophthalmology (Auckland, N.Z.)|October 29, 2011
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomesTimothy W Morris, Lynne S Gearinger, Dale W Usner, et al.
Ophthalmology|August 5, 2011
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trialP Andrew Pearson, Timothy L Comstock, Michael Ip, et al.
Current Medical Research and Opinion|March 28, 2009
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisMichael E Tepedino, Warren H Heller, Dale W Usner, et al.
Ophthalmology|August 1, 2009
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisMarguerite B McDonald, Eugene E Protzko, Lynne S Brunner, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|October 10, 2007
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implantsDebra A Goldstein, David G Godfrey, Anthony Hall, et al.
Clinical Therapeutics|April 28, 2009
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyPaul Karpecki, Michael Depaolis, Judy A Hunter, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 23, 2015
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgeryFrank A Bucci, Ruth E Evans, Loretta M Amico, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Clinical Ophthalmology (Auckland, N.Z.)|October 29, 2011
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomesTimothy W Morris, Lynne S Gearinger, Dale W Usner, et al.
Ophthalmology|August 5, 2011
Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trialP Andrew Pearson, Timothy L Comstock, Michael Ip, et al.
Current Medical Research and Opinion|March 28, 2009
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisMichael E Tepedino, Warren H Heller, Dale W Usner, et al.
Ophthalmology|August 1, 2009
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitisMarguerite B McDonald, Eugene E Protzko, Lynne S Brunner, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|October 10, 2007
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implantsDebra A Goldstein, David G Godfrey, Anthony Hall, et al.
Clinical Therapeutics|April 28, 2009
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyPaul Karpecki, Michael Depaolis, Judy A Hunter, et al.
Clinical Ophthalmology (Auckland, N.Z.)|May 23, 2015
Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgeryFrank A Bucci, Ruth E Evans, Loretta M Amico, et al.
Pageof 4